On Thursday, Aeropostale Inc (NYSE:ARO)’s shares declined -5.33% to $1.42.
An improving economy driven by the housing market’s “wealth effect” should assist a restaurant chain like Ruby Tuesday’s (RT) and apparel and accessory retailer Aeropostale (ARO).
The Radical Consumerist, is an Investment Newsletter focused on discovering and showcasing high-yield investment opportunities together with breaking news and analysis geared at maximizing returns for ordinary investors in the consumer products space.
The middle and lower classes in America are struggling and experiencing declines in real income. The United States is the only developed economy that has the distinction of more people living on less than $50 per day than a decade earlier.
According to a Pew Research Center report, the share of Americans living on more than $50 a day fell to 56% in 2011 contrast with 58% in 2001. Median income also fell in the U.S. to $56.44 from $58.56.
Along these lines, median income fell in the United States from $53,646 in 2001 to $50,054 in 2011. This decline puts the U.S. in the same group as Nicaragua, the Philippines, Dominican Republic, El Salvador, Bulgaria and Serbia.
Aéropostale, Inc. operates as a specialty retailer of casual apparel and accessories for 14 to 17 year-old young women and men. It operates through two segments, Retail Stores and E-Commerce, and International Licensing. The company also offers casual clothing and accessories focusing on kids between the ages of 4 to 12 year olds. As of March 24, 2015, it operated 766 Aéropostale stores in 50 states and Puerto Rico, 61 Aéropostale stores in Canada, and 26 P.S. from Aéropostale stores in 12 states and Puerto Rico. In addition, the company markets its products through ps4u.com and aeropostale.com, in addition to its licensees operate 251 Aéropostale and P.S. from Aéropostale locations in the Middle East, Asia, Europe, and Latin America under various licensing agreements. Further, it operates GoJane.com that retails in fashion footwear, contemporary apparel, and other accessories for women online. Aéropostale, Inc. has a planned partnership with Sycamore Partners.
SeaWorld Entertainment Inc (NYSE:SEAS)’s shares dropped -1.33% to $18.52.
SeaWorld Entertainment, Inc. (SEAS), a leading theme park and entertainment company, stated financial results for the first half and second quarter of 2015.
Overview
- Stated an attendance decline in the second quarter due to the timing of Easter, record levels of rainfall in Texas and continued brand challenges in California, partially offset by improvements in demand at the Company’s other park locations, counting Florida.
- Accomplished a debt refinancing, which, at current interest rates, should generate an average of $14.0 million in annual interest cost savings.
- Returned $54.5 million to shareholders through dividend declarations thus far in 2015.
- Reaffirmed full year 2015 Adjusted EBITDA guidance to be in the range of flat to up 3% as compared to 2014.
SeaWorld Entertainment, Inc. operates as a theme park and entertainment company in the United States. The company operates marine-life theme park under the SeaWorld brand name in Orlando, San Antonio, and San Diego; Busch Gardens theme parks, which are family-oriented destinations with foreign geographic settings in Tampa and Williamsburg; Discovery Cove marine-life theme park in Langhorne; and Sesame Place, a seasonal park in Langhorne.
At the end of Thursday’s trade, Natera Inc (NASDAQ:NTRA)‘s shares dipped -4.83% to $15.56.
Natera, Inc. (NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, recently stated financial results for the second quarter ended June 30, 2015 and offered an update on recent business progress.
Recent Accomplishments & Highlights
- Achieved Total Revenue of $45.1 million in the second quarter of 2015, an enhance of 26% over the same period of the preceding year.
- Accessioned roughly 69,000 tests in the second quarter of 2015 contrast to roughly 54,000 tests accessioned in the second quarter of 2014, an enhance of 28%.
- Accomplished a successful initial public offering, resulting in net proceeds to Natera of about $178.5 million, counting $15.1 million from the exercise of the underwriters’ overallotment option.
Natera, Inc., a genetic testing company, develops and commercializes non-invasive methods for analyzing deoxyribonucleic acid (DNA) in the United States and Europe. The company primarily offers Panorama, a non-invasive prenatal test for fetal chromosomal abnormalities; Horizon test; and pre-implantation genetic screening and pre-implantation genetic diagnosis tests under the Spectrum brand to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization.
Sanofi SA (ADR) (NYSE:SNY), ended its Thursday’s trading session with -0.19% loss, and closed at $-0.19.
Sanofi SA (ADR) (SNY) and Regeneron Pharmaceuticals, Inc. declared that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) recommended the approval of the investigational therapy Praluent® (alirocumab) Injection. The Committee voted 13 to 3 (with no abstentions) that Sanofi and Regeneron had sufficiently established that the low-density lipoprotein cholesterol (LDL-C, or bad cholesterol) lowering benefit of Praluent exceeds its risks to support approval in one or more patient populations.
The Committee’s recommendation was based on Praluent’s benefit-risk profile, following review of efficacy and safety data from more than 5,000 patients across 10 pivotal Phase 3 double-blind trials ranging from six months to two years. Clinical data from the ODYSSEY Phase 3 program show comprising, positive results in reducing LDL-C. Common adverse events that were more frequently stated in patients treated with Praluent than the control groups comprised of injection site reaction and pruritus (itching).
Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, counting Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, in addition to Toujeo, an insulin glargine.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
